CA-GLOBALLOGIC-INC.
GlobalLogic Inc. ,1 a Hitachi Group company and leader in Digital Engineering, today announced the availability of its enhanced Microservices Accelerator, a comprehensive and pluggable digital microservices development platform. Developed by GlobalLogic, this technology is used in conjunction with the company’s Digital Engineering services to greatly simplify and accelerate the design, configuration, and deployment of Microservices platforms – which are the most commonly deployed architectures in creating new digital experiences.
Notably, the Microservices Accelerator is currently the foundation platform for many GlobalLogic clients including EyeCare Partners , the leading healthcare service provider for optometry and ophthalmology; Petplan , the most comprehensive pet health care insurance in North America; and DISA Global Solutions , the leading provider of safety, compliance, and screening services.
Part of GlobalLogic’s Digital Accelerators product offerings, the Microservices Accelerator provides a complete solution that includes a project configurator and a set of pluggable modules that perform the most common Non-Functional Requirements (NFRs) required by any microservices-based deployment. The latest release introduces advanced capabilities including CloudEvents support, security framework upgrades, and ETag support to enhance caching capabilities.
Digital Accelerator Key Value Proposition
Driving the accelerator’s development were Independent Software Vendors (ISVs), enterprises, and startup company needs. As more companies move their product offerings to cloud-native platforms, developers seek codified tools that can efficiently address and automate common, time-consuming processes. Early results have shown a savings of up to 75 person months for a typical large-size deployment project, which means significantly reduced time to market, a more reliable and repeatable process, and increased ROI.
“Having deployed many such platforms over the last couple of years, GlobalLogic has established a strong body of knowledge that we have included in this toolset — ranging from enterprise-scale capabilities to best practices. Our clients are already shaving off months from the bootstrap, and reducing overall implementation costs and effort with our solution,” said Piyush Jha , SVP & Chief of Technology and Strategy (APAC), GlobalLogic.
“Microservices is a great architectural paradigm that takes modularity to the next level and, in many ways, is fundamental for achieving the massive scale requirements of modern software,” said Deepak Gupta , SVP & Global Head of Technology Practices, GlobalLogic. “This accelerator is an out-of-box solution that allows engineers to set up complex architectures in a single day, rather than the months typically required. Moreover, it provides a required guardrail to operate within, and reduces the possibilities of human error — which is essential to being successful with this programming paradigm.”
Inter-Company Deployment
As part of Hitachi’s acquisition of GlobalLogic, the accelerator technology will be utilized in Hitachi's services and solutions going forward.
“Hitachi Application Services Division is excited to leverage the GlobalLogic Accelerators in its service delivery schema,” said Emi Goto, Senior Director, Application Services Division, Hitachi, Ltd. “The growth of our Lumada business will be accelerated in the expanding Digital Transformation market by combining the innovativeness of GlobalLogic's Experience Design and Chip-to-Cloud software engineering with Hitachi's enterprise application delivery experiences in mission critical systems.”
GlobalLogic’s Microservices Accelerator supports both containers and functions as a service-based deployment model across cloud hyperscalers Microsoft Azure, AWS, and Google Cloud Platform (GCP).
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005358/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom